A player in the oncology field since 1978, Pierre Fabre has been busy this month advancing its cancer ambitions through a pact with Vernalis (R&D) Ltd. and the acquisition of Vertical Bio.
The French group has linked up with Vernalis, formerly one of the jewels of the UK biotech sector and now a subsidiary of China's HitGen Inc., with "a long-term partnership" to identify preclinical candidates against multiple oncology targets